Undisclosed brain penetrant TRPML1 agonist / Lysoway Therapeutics - LARVOL DELTA

Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson’s Disease (Businesswire) - "Lysoway Therapeutics, Inc...announced that it has received a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). Support comes from MJFF’s Parkinson’s Disease Therapeutics Pipeline Program, which focuses on candidates with strong potential to slow or halt disease progression or alleviate burdensome symptoms for those living with Parkinson’s disease. Lysoway Therapeutics funding of $2.93 million will support the preclinical and translational development of Lysoway’s novel, highly brain-penetrant small molecule TRPML1 agonist."

Financing • Parkinson's Disease